Strategic Partnerships ArmaGen is actively leveraging licensing and collaboration agreements to advance its brain-penetrant therapies, presenting opportunities for co-development, licensing, or commercialization partnerships with biopharma looking to enter CNS markets.

Neurological Focus Pipeline emphasis on lysosomal storage disorders with CNS involvement (Hurler, Hunter, MPS, Sanfilippo) creates potential for partnerships with specialty distributors and patient advocacy groups targeting orphan CNS diseases.

Funding & Growth With $35M in funding and modest revenue, there is runway for BD initiatives to secure strategic investments, milestone-driven deals, or out-licensing of early programs to de-risk and scale commercial potential.

IP Strength A dominant intellectual property portfolio around brain-penetrant therapies can be a key differentiator in negotiations, enabling licensing conversations with firms seeking robust CNS tech platforms.

Leadership & Continuity Longstanding leadership with prior CEO appointments indicates stable leadership for partnerships, while past collaborations (notably with Shire) signal a history of successful alliance formation worth revisiting.